BACKGROUND AND OBJECTIVES: Cytomegalovirus (CMV) disease remains an important complication of allogeneic stem cell transplantation (SCT). We studied viral load kinetics and correlated the viral load and other transplant factors with the development of CMV disease. DESIGN AND METHODS: We studied 162 consecutive patients who were CMV seropositive or had CMV seropositive donors. Quantification of CMV DNA was performed by real-time polymerase chain reaction. RESULTS: CMV DNA detected was detected in 105 of the 162 patients. The mean peak viral loads were similar at first and subsequent reactivations. The serologic status of the donors and recipients prior to SCT significantly influenced the viral load. The cumulative incidence of CMV disease was 1.8% at 100 days and 6.3% at 365 days after SCT. The peak viral load were higher in patients who developed CMV disease than in patients without CMV disease (log10 3.5; SE +/- 0.26/200,000 cells vs. log10 2.7; SE +/- 0.09/200,000 cells; p=0.02). However, in multivariate analysis, only acute graft-versus-host disease (GVHD) grade II-IV and a graft from a CMV-negative donor to a CMV-positive patient were significant risk factors for CMV disease. In patients who required more than one course of pre-emptive therapy, acute GVHD and the rate of decrease in viral load during first pre-emptive therapy were significant risk factors for subsequent development of CMV disease. INTERPRETATION AND CONCLUSIONS: A decrease in viral load during pre-emptive therapy is an important factor for later development of CMV disease.
BACKGROUND AND OBJECTIVES: Cytomegalovirus (CMV) disease remains an important complication of allogeneic stem cell transplantation (SCT). We studied viral load kinetics and correlated the viral load and other transplant factors with the development of CMV disease. DESIGN AND METHODS: We studied 162 consecutive patients who were CMV seropositive or had CMV seropositive donors. Quantification of CMV DNA was performed by real-time polymerase chain reaction. RESULTS: CMV DNA detected was detected in 105 of the 162 patients. The mean peak viral loads were similar at first and subsequent reactivations. The serologic status of the donors and recipients prior to SCT significantly influenced the viral load. The cumulative incidence of CMV disease was 1.8% at 100 days and 6.3% at 365 days after SCT. The peak viral load were higher in patients who developed CMV disease than in patients without CMV disease (log10 3.5; SE +/- 0.26/200,000 cells vs. log10 2.7; SE +/- 0.09/200,000 cells; p=0.02). However, in multivariate analysis, only acute graft-versus-host disease (GVHD) grade II-IV and a graft from a CMV-negative donor to a CMV-positive patient were significant risk factors for CMV disease. In patients who required more than one course of pre-emptive therapy, acute GVHD and the rate of decrease in viral load during first pre-emptive therapy were significant risk factors for subsequent development of CMV disease. INTERPRETATION AND CONCLUSIONS: A decrease in viral load during pre-emptive therapy is an important factor for later development of CMV disease.
Authors: Margaret L Green; Wendy Leisenring; Daniel Stachel; Steven A Pergam; Brenda M Sandmaier; Anna Wald; Lawrence Corey; Michael Boeckh Journal: Biol Blood Marrow Transplant Date: 2012-06-07 Impact factor: 5.742
Authors: Bryan T Alexander; Lindsay M Hladnik; Kristan M Augustin; Ed Casabar; Peggy S McKinnon; Richard M Reichley; David J Ritchie; Peter Westervelt; Erik R Dubberke Journal: Pharmacotherapy Date: 2010-06 Impact factor: 4.705
Authors: Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh Journal: Biol Blood Marrow Transplant Date: 2009-10 Impact factor: 5.742
Authors: Shivaprasad Manjappa; Pavan Kumar Bhamidipati; Keith E Stokerl-Goldstein; John F DiPersio; Geoffrey L Uy; Peter Westervelt; Jingxia Liu; Mark A Schroeder; Ravi Vij; Camille N Abboud; Todd A Fehniger; Amanda F Cashen; Iskra Pusic; Meagan Jacoby; Srinidhi J Meera; Rizwan Romee Journal: Biol Blood Marrow Transplant Date: 2013-10-10 Impact factor: 5.742
Authors: Filippo Milano; Steven A Pergam; Hu Xie; Wendy M Leisenring; Jonathan A Gutman; Ivy Riffkin; Victor Chow; Michael J Boeckh; Colleen Delaney Journal: Blood Date: 2011-09-21 Impact factor: 22.113
Authors: Angela P Campbell; Jason W Chien; Jane Kuypers; Janet A Englund; Anna Wald; Katherine A Guthrie; Lawrence Corey; Michael Boeckh Journal: J Infect Dis Date: 2010-05-01 Impact factor: 5.226